Letter of intent for the submission of a worksharing procedure to the European Medicines Agency according to Article 65 of Regulation (EU) 2019/6

Human medicines European public assessment report (EPAR): Jemperli, dostarlimab, Date of authorisation: 21/04/2021, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Ogluo, glucagon, Date of authorisation: 11/02/2021, Revision: 8, Status: Authorised

Human medicines European public assessment report (EPAR): Roclanda, latanoprost / netarsudil, Date of authorisation: 07/01/2021, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Abecma, idecabtagene vicleucel, Date of authorisation: 18/08/2021, Revision: 13, Status: Authorised

Human medicines European public assessment report (EPAR): Conexxence, denosumab, Date of authorisation: 18/07/2025, Status: Authorised

Quick guide to competing interests for EMA experts

Questions and answers on Implementing Regulation (EU) 2025/1466: Amendment of Regulation (EU) No 520/2012 and Conclusion of the Signal Detection in EudraVigilance Pilot by marketing authorisation holders

Article 57 product data

Human medicines European public assessment report (EPAR): Cabometyx, cabozantinib, Date of authorisation: 09/09/2016, Revision: 19, Status: Authorised